Free Newsletter
Insurance fears make volunteers balk at AIDS trial
A professor at the University of Toronto is warning that researchers may find it increasingly difficult to enlist volunteers for new trials exploring the safety and efficacy of experimental AIDS vaccines. Peter Newman interviewed a group of volunteers who had opted out of Merck's international STEP program and found a common fear that they would test positive for HIV because of the antibodies produced by the vaccine.
Their response: "This could change your life," says Newman. "We are not talking about getting little round spots on your hands or something. We are talking about showing up positive. How can you tell your doctor, your insurance company? Like, how do you deal with that? Because this has a huge stigma for people."
The group also demonstrated a fear they would be denied life insurance or find it difficult to explain a positive test to a prospective partner. But all the reasons add up to one major concern: future AIDS vaccine trials are likely to run into some serious obstacles in gaining enough volunteers for accurate testing.
- read the article from CBC
Related Articles:
Long delay seen for Merck's AIDS vaccine. Report
Gilead hesitant to tout drug for AIDS prevention. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




